Healthcare Industry Developments | BioTuesdays by Kilmer Lucas IR

Developments

NeuroSense reports positive biomarker study in Alzheimer’s

NeuroSense Therapeutics (NASDAQ:NRSN) reported positive results from a biomarker study conducted to evaluate the potential of CogniC, NeuroSense’s combination drug for the treatment of Alzheimer’s disease...

June 30, 2022

Developments

Domain Therapeutics receives multimillion-dollar milestone from Merck

Domain Therapeutics, which operates in France and Canada, obtained a single-digit multimillion-dollar milestone payment from Merck as part of a €240 million collaboration and license partnership signed in 2017. Drug...

June 30, 2022

Developments

Palisade Bio initiates Phase 3 study for postoperative return of bowel function

Palisade Bio (NASDAQ:PALI) initiated a Phase 3 study evaluating LB1148 to accelerate the return of bowel function in adult patients undergoing gastrointestinal surgery. The first clinical site in the U.S. is now open...

June 29, 2022

Developments

ENDRA receives 28th U.S. patent for TAEUS system

The United States Patent and Trademark Office has issued a new ENDRA Life Sciences (NASDAQ:NDRA) patent to protect its TAEUS’ radiofrequency (RF) applicator for optimizing the delivery of RF energy to tissue. The...

June 28, 2022

Developments

NeuroSense posts positive results from stage 3 ALS biomarker study

NeuroSense Therapeutics (NASDAQ:NRSN) reported positive results from stage 3 of its biomarker study conducted in collaboration with Massachusetts General Hospital to evaluate PrimeC, NeuroSense’s lead combination...

June 27, 2022

Developments

Zucara Therapeutics reports positive results from Phase 1b trial in T1D

Closely held Zucara Therapeutics reported that its Phase 1b proof-of-concept trial demonstrated ZT-01’s ability to restore glucagon release in people with Type 1 diabetes. Data from 18 subjects that completed all three...

June 22, 2022

Developments

Hepion receives FDA orphan drug designation for rencofilstat in HCC

The FDA granted orphan drug designation to Hepion Pharmaceuticals’ (NASDAQ:HEPA) drug candidate, rencofilstat, a liver-targeting, orally administered, novel cyclophilin inhibitor, for the treatment of hepatocellular...

June 20, 2022

Developments

FDA clears Rhythm Pharma’s IMCIVREE in Bardet-Biedl Syndrome

The FDA has approved Rhythm Pharmaceuticals’ (NASDAQ:RYTM) supplemental NDA for IMCIVREE (setmelanotide) for patients with Bardet-Biedl syndrome (BBS). IMCIVREE is indicated for chronic weight management in adult and...

June 17, 2022

Developments

Hepion to present 5 posters at EASL International Liver Congress 2022

Hepion Pharmaceuticals (NASDAQ:HEPA) said five abstracts have been accepted for poster presentations at the European Association for the Study of the Liver (EASL) International Liver Congress taking place June 22...

June 15, 2022

Developments

Rhythm Pharma presents setmelanotide data at ENDO 2022

Rhythm Pharmaceuticals (NASDAQ:RYTM) and its collaborators presented new data at the Endocrine Society annual meeting from the company’s long-term extension trial with setmelanotide, which show continued body mass...

June 13, 2022

Developments

LENSAR receives FDA clearance of ALLY Adaptive Cataract Treatment System

The FDA cleared LENSAR’s (NASDAQ:LNSR) next-generation ALLY Adaptive Cataract Treatment System to enable cataract surgeons to complete the femtosecond-laser-assisted cataract surgery procedure seamlessly in a single...

June 13, 2022

Developments

Tonix Pharma TNX-1500 data presented at American Transplant Congress

Faculty at the Center for Transplantation Sciences, Massachusetts General Hospital, presented data at the 2022 American Transplant Congress about Tonix Pharmaceuticals’ (NASDAQ:TNXP) TNX-1500 product candidate in...

June 9, 2022

Developments

PharmaJet sponsor study published in The Lancet

A Phase 3 clinical study sponsored by PharmaJet’s partner, Zydus Lifesciences, featuring ZyCoV-D, the world’s first plasmid-DNA vaccine approved for use in humans and delivered by the PharmaJet Tropis Intradermal needle...

June 8, 2022

Developments

Qualigen acquires majority stake in NanoSynex

Qualigen Therapeutics (NASDAQ:QLGN) completed the acquisition of a majority stake in NanoSynex, an Israeli-based developer of next generation diagnostics technology. In a statement, Michael Poirier, chairman and CEO of...

June 2, 2022

Developments

NeuroSense enrolls first patient in Phase 2b ALS Trial with PrimeC

NeuroSense Therapeutics (NASDAQ:NRSN) enrolled the first patient in its Phase 2b PARADIGM trial for its lead drug candidate, PrimeC, for the treatment of amyotrophic lateral sclerosis (ALS). PARADIGM will enroll 69...

June 1, 2022

Developments

Hepion highlights upcoming Phase 2 rencofilstat trials at NASH Congress

Todd Hobbs, M.D. and CMO of Hepion Pharmaceuticals (NASDAQ:HEPA), gave a clinical presentation entitled, “Rencofilstat (CRV431): A liver-targeting drug candidate for NASH and HCC” at the Global NASH Congress...

May 27, 2022

Developments

Cowen sees continued demand for Profound’s TULSA-PRO after AUA2022

“We continue to gain confidence in the disruptive potential of Profound Medical’s (NASDAQ:PROF; TSX:PRN) transurethral directional thermal ultrasound ablation treatment for prostate cancer, TULSA-PRO,” writes Cowen...

May 20, 2022

Developments

MindMed reports Phase 1 topline data with MM-110 in opioid withdrawal

Mind Medicine (NASDAQ:MNMD; NEO:MMED) reported favorable safety and tolerability results from a Phase 1 placebo-controlled trial designed to assess safety, tolerability, pharmacokinetics and neurocognitive effects of MM...

May 19, 2022

Developments

Profound Medical insiders add to holdings

Profound Medical (NASDAQ:PROF; TSX:PRN) independent lead director, Brian Ellacott, and chairman and CEO, Arun Menawat, purchased additional shares of Profound on Nasdaq after the company’s 2022 first quarter blackout...

May 19, 2022

Developments

Profound Medical’s TULSA-PRO front and center at AUA2022

The American Urological Association’s 2022 annual meeting featured multiple clinical presentations and product demonstrations of Profound Medical’s (NASDAQ:PROF; TSX:PRN) TULSA-PRO to effectively and safely ablate...

May 18, 2022

Developments

Ampio board committee conducting internal investigation

An independent special committee of the board of Ampio Pharmaceuticals (NYSE American:AMPE), with the assistance of independent legal counsel, is in the process of conducting an internal investigation that relates to...

May 17, 2022

Developments

Lanier Biotherapeutics to present LNR125 poster at American Thoracic Society

Lanier Biotherapeutics will present a poster demonstrating the ability of its LNR 125 to inhibit Type 2 inflammation in models of asthma caused by both allergy and respiratory viral infection at the American Thoracic...

May 13, 2022

Subscribe